Read More Pharma Industry News Sai Life Sciences (NSE: SAILIFE) Q2 FY26 profit doubles on CRDMO demand, high-value tech expansion Sai Life Sciences profit doubled in Q2 FY26, driven by peptide, ADC, and oligo expansion. See how the CRDMO firm is gaining margin and investor traction. byVenkateshNovember 7, 2025